Diagnostic performance of contrast-enhanced CT, Diffusion-weighted MRI and FDG-PET in pleural thickening -Prospective study

Phase 4

• Conditions: Mesothelioma

• Registration Number: JPRN-UMIN000011771
• Lead Sponsor: Saitama Medical University International Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-09-16
• Study Completion: 2018-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients in whom pathological diagnosis was made 2) Patients who underwent invasive treatment 3) Patients for whom the investigator or subinvestigator(s) judges their participation in the clinical trial to be inappropriate 4) Patients in whom MRI examination is contraindicated (e.g., use of a pacemaker) 5) Patients in whom iodine-based and Gd-based contrast media are contraindicated (e.g., patients with a history of hypersensitivity to these contrast media)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The overall abilities (sensitivity, specificity, and accuracy) to diagnose mesothelioma, disseminated lung cancer, and benign pleural disease (e.g., pleurisy) of various modalities (i.e., contrasted CT, DWI-MRI, and FDG-PET) are compared with those from definite diagnosis.

Secondary Outcome Measures

Name	Time	Method
•Characteristic appearances are examined for mesothelioma, disseminated lung cancer, and benign pleural disease (pleurisy). •Diagnostic performance (sensitivity, specificity, and accuracy) is compared among various modalities (i.e., contrasted CT, DWI-MRI, and FDG-PET).